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Introduction and history: The glycogen storage disorders may show two 
different presentations. One group present with permanent and progressive 
weakness (such as GSD II, GSD III and GSD IV).Another group have 
intermittent episodes of weakness, muscle pain and/or myoglobinuria(such 
as Mc Ardle disease). Glycogen storage disease type 2 is caused by acid 
maltase deficiency. GSD II is an autosomal recessive disorder  that was 
first described by Dutch pathologist Joannes C. Pompe in 1932. And can 
be categorized into two types, based on the age of onset of disease and 
degree of organ involvement: infantile (the most severe presentation),and 
late type (childhood and  adult). Pompe disease is caused by deficiency of 
the lysosomal enzyme acid alpha-glucosidase (GAA) or acid maltase. and 
is  the only members of glycogen storage diseases that is classified also as a 
lysosomal storage disorder.
•	 genetic and Pathology: The incidence of pompe disease has been 
estimated to be 1 in 40,000 live births and its prevalence about 1 in 
146000. The defective gene is located on chromosome 17q25.2-25.3.The 
main pathologic feature of pompe disease is a vacuolar myopathy 
and intralysosomal accumulation of glycogen in cardiac, skeletal and 
smooth muscle fibers, but there is also aggregation of large amounts of 
PAS positive materials in another sites (liver, renal tubules, anterior horn 
cells of spinal cord and brain stem nuclei).
Clinical features: Acid maltase has no function in maintaining blood 
glucose; therefore hypoglycemia is not a feature of this disease. Because 
hypotonia and muscle weakness are part of manifestations of this disease, it 
has also been classified as a neuromuscular disease or a metabolic myopathy. 
Symptoms of infantile pompe disease may begin from neonatal period, but 
usually appear at a mean age of 1-2 months. Initial symptoms are profound 
hypotonia without atrophy, feeding difficulties, weakness and respiratory 
impairment. These patients have little spontaneous movements and weak 
cry. Gradually cardiomegaly and respiratory insufficiency 
develops and serial echocardiography shows progressive left ventricular 
enlargement. Macroglossia and Hepatosplenomegaly are also present. Deep.
tendon reflexes are progressively lost due to anterior horn cell involvement. 
Without enzyme replacement therapy (ERT), pompe disease ultimate’s in 
profound generalized weakness and hypertrophic cardiomyopathy with 
rapid progression to death occurring before 2 years of age. Late- onset forms 
of pompe disease including childhood, juvenile and adult type usually show 
progressive proximal muscle weakness and typically not including severe 
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prick, finger stick, or blood draw has prepared rapid 
detection of pompe disease. This test is also suitable 
for newborn screening test but it should be mentioned 
that positive result of this test in not enough for 
definite diagnosis and a second confirmatory test 
such as fibroblast enzyme study or genetic mutation 
analysis, is needed.
Differential Diagnosis: Since pompe disease is a 
rare condition and on the other hand its symptoms 
are nonspecific, the diagnosis of this disorder poses a 
diagnostic dilemma. The most important differential 
diagnosis of infantile pompe disease have been shown 
in table 1.
Management: Pompe disease needs to a 
multidisciplinary team to handle its multisystem 
disturbances. Before the last few years there was 
no practical treatment for pompe disease. Enzyme 
replacement therapy (ERT) became available in the 
late 1990s and Myozyme received FDA approval 
for acid maltase deficiency in 2006. Children with 
infantile Pompe disease are now surviving beyond 
infancy with some gaining independent walking and 
level of daily activity never before possible.  
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cardiomyopathy(or absence of cardiomyopathy).
Laboratory tests: EKG in these patients reveals 
abnormalities, including short PR intervals, depressed 
ST segment, inverted T wave and high QRS 
complexes. The CXR shows massive cardiomegaly 
and EMG illustrates myopathic changes. Other useful 
diagnostic tests are echocardiography and pulmonary 
function test that can demonstrate hypertrophic 
cardiomyopathy and respiratory compromise, 
respectively .Elevated creatine kinase(CK) levels is 
seen(as high as 2000 UI/L). Evaluation of muscle 
and liver biopsy by light and electron microscopy 
demonstrates large amounts of glycogen with normal 
structure, although abscence of glycogen in muscle 
biopsy is not against the diagnosis of pompe disease. 
Measurement of acid alpha glucosidase activity 
by using skin biopsy and culture of fibroblasts or 
purified lymphocytes from peripheral blood smear 
is diagnostic. Molecular genetic testing, mutation 
analysis and prenatal diagnosis are available. There is 
increasing evidence of the value of a specific glucose 
tetrasaccaride (GLc4) in urine which has near to 
100% sensitivity in detecting patients with infantile 
pompe disease. Nowadays, Dried Blood Spot test 
(DBS) in which blood sample obtained by heel 
Tab.1: Differential diagnosis of infantile pompe disease
Differential Diagnoses Shared Signs & Symptoms
1-Spinal muscular atrophy I(SMA I) Hypotonia, Progressive proximal muscle weakness, Absent reflexes, Feeding difficulties, Elevated creatine kinase (CK)
2-Hypothyroidism Hypotonia, Macroglossia
3-Congenital muscular dystrophy Hypotonia (severe),Muscle weakness
4-Danon disease Hypertrophic cardiomyopathy, Skeletal muscle myopathy, Vacuolar glycogen storage, Elevated CK
5-Carnitine deficiency Cardiomyopathy, Muscle weakness
6-Glycogen storage diseases (GSD) III & IV Hepatomegaly, Hypotonia, Cardiomegaly, Muscle weakness, Elevated CK
7-Myocarditis, Idiopathic hypertrophic     
cardiomyopathy Biventricular hypertrophy, Cardiomegaly
8-Peroxisomal disorders Hypotonia, Hepatomegaly
9-Mitochondrial/respiratory chain disorders Hepatomegaly, Cardiomyopathy, Myopathy, Elevated CK
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